Article Text

other Versions

Download PDFPDF
Original article
Sleep-disordered breathing, impaired cardiac adrenergic innervation and prognosis in heart failure
  1. Oriana Scala1,2,
  2. Stefania Paolillo3,
  3. Roberto Formisano4,
  4. Teresa Pellegrino5,6,
  5. Giuseppe Rengo4,7,
  6. Paola Gargiulo3,
  7. Fausto De Michele8,
  8. Antonio Starace8,
  9. Antonio Rapacciuolo1,
  10. Valentina Parisi4,
  11. Maria Prastaro1,
  12. Valentina Piscopo5,
  13. Santo Dellegrottaglie9,
  14. Dario Bruzzese10,
  15. Fabiana De Martino1,
  16. Antonio Parente1,
  17. Dario Leosco4,
  18. Bruno Trimarco1,
  19. Alberto Cuocolo3,5,
  20. Pasquale Perrone-Filardi1
  1. 1Department of Advanced Biomedical Sciences, Section of Cardiology, Federico II University, Naples, Italy
  2. 2Cardiovascular Department, IRCCS MultiMedica, Sesto San Giovanni, Italy
  3. 3SDN Foundation, Institute of Diagnostic and Nuclear Development, Naples, Italy
  4. 4Department of Translational Medical Sciences, Section of Geriatrics, Federico II University, Naples, Italy
  5. 5Department of Advanced Biomedical Sciences, Section of Imaging, Radiotherapy, Neuroradiology and Medical Physics, Federico II University, Naples, Italy
  6. 6Institute of Biostructures and Bioimages of the National Council of Research, Naples, Italy
  7. 7Division of Cardiology, “Salvatore Maugeri” Foundation—IRCCS—Institute of Telese Terme (BN), Telese Terme, Italy
  8. 8Dipartimento Onco-Pneumo-Ematologia, UOC Pneumologia 1 e Fisiopatologia Respiratoria, AORN A. Cardarelli, Naples, Italy
  9. 9Istituto Diagnostico Varelli, Naples, Italy
  10. 10Department of Public Health, Federico II University, Naples, Italy
  1. Correspondence to Professor Pasquale Perrone-Filardi, Department of Advanced Biomedical Sciences, Federico II University, Via Pansini 5, Naples 80131, Italy; fpperron{at}


Objective Unfavourable effects of sleep-disordered breathing (SDB) in heart failure (HF) are mainly mediated by impaired sympathetic activity. Few data are available on SDB and cardiac adrenergic impairment evaluated at myocardial level. The aim of the study was to assess the relationship between SDB, cardiac sympathetic innervation assessed by 123I-metaiodobenzylguanidine (123I-MIBG) imaging and prognosis in HF.

Methods Observational, prospective study enrolling patients with HF and reduced systolic function. Patients underwent nocturnal cardiorespiratory monitoring to assess SDB presence by apnoea/hypopnoea index (AHI), and 123I-MIBG imaging to calculate heart-to-mediastinum (H/M) ratios and washout rate. Patients were prospectively followed for 29±18 months for the combined endpoint of cardiovascular death and HF hospitalisation.

Results Ninety-four patients (66.1±9.8 years; left ventricular ejection fraction 32±7%) were enrolled; 72 (77%) showed SDB and, compared with non-SDB, significantly reduced early (1.67±0.22 vs 1.77±0.13; p=0.019) and late H/M ratios (1.50±0.22 vs 1.61±0.23; p=0.038). Dividing patients into two groups according to SDB severity, patients with a moderate–severe disturbance (AHI >15; n=43) showed significantly worse survival for the composite study outcome (log-rank test, p=0.001) with respect to patients with mild or no disorder (AHI ≤15; n=51). Adding SDB variables to the already known prognostic role of 123I-MIBG imaging, we observed a worse survival in patients with both SDB and H/M impairment.

Conclusions Patients with systolic HF and SDB show more impaired cardiac adrenergic innervation assessed by 123I-MIBG imaging, and more adverse prognosis compared with HF patients without SDB.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.